Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients.

Hakobyan L, Haaijer-Ruskamp FM, de Zeeuw D, Dobre D, Denig P.

Health Qual Life Outcomes. 2011 Sep 29;9:83. doi: 10.1186/1477-7525-9-83. Review.

2.

Comparing adverse event rates of oral blood glucose-lowering drugs reported by patients and healthcare providers: a post-hoc analysis of observational studies published between 1999 and 2011.

Hakobyan L, Haaijer-Ruskamp FM, de Zeeuw D, Dobre D, Denig P.

Drug Saf. 2011 Dec 1;34(12):1191-202. doi: 10.2165/11593810-000000000-00000.

PMID:
22077507
3.

Methods for assessing the preventability of adverse drug events: a systematic review.

Hakkarainen KM, Andersson Sundell K, Petzold M, Hägg S.

Drug Saf. 2012 Feb 1;35(2):105-26. doi: 10.2165/11596570-000000000-00000. Review.

4.

Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.

Heather EM, Payne K, Harrison M, Symmons DP.

Pharmacoeconomics. 2014 Feb;32(2):109-34. doi: 10.1007/s40273-013-0120-z. Review.

PMID:
24338344
5.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
6.

Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.

Hemmingsen B, Schroll JB, Lund SS, Wetterslev J, Gluud C, Vaag A, Sonne DP, Lundstrøm LH, Almdal T.

Cochrane Database Syst Rev. 2013 Apr 30;(4):CD009008. doi: 10.1002/14651858.CD009008.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;(7):CD009008.

PMID:
23633364
7.

Association between pacifier use and breast-feeding, sudden infant death syndrome, infection and dental malocclusion.

Callaghan A, Kendall G, Lock C, Mahony A, Payne J, Verrier L.

JBI Libr Syst Rev. 2005;3(6):1-33.

PMID:
27819973
8.

Incidence, preventability, and impact of Adverse Drug Events (ADEs) and potential ADEs in hospitalized children in New Zealand: a prospective observational cohort study.

Kunac DL, Kennedy J, Austin N, Reith D.

Paediatr Drugs. 2009;11(2):153-60. doi: 10.2165/00148581-200911020-00005.

PMID:
19301935
9.

A systematic review of utility values for chemotherapy-related adverse events.

Shabaruddin FH, Chen LC, Elliott RA, Payne K.

Pharmacoeconomics. 2013 Apr;31(4):277-88. doi: 10.1007/s40273-013-0033-x. Review.

PMID:
23529208
10.

Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.

Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology.

Stroke. 2003 Aug;34(8):e109-37. Epub 2003 Jul 17. Erratum in: Stroke. 2003 Nov;34(11):2774.

11.
12.

Occurrence and preventability of adverse drug events in surgical patients: a systematic review of literature.

Boeker EB, de Boer M, Kiewiet JJ, Lie-A-Huen L, Dijkgraaf MG, Boermeester MA.

BMC Health Serv Res. 2013 Sep 28;13:364. doi: 10.1186/1472-6963-13-364. Review.

13.

Hospital admissions caused by adverse drug events: an Australian prospective study.

Phillips AL, Nigro O, Macolino KA, Scarborough KC, Doecke CJ, Angley MT, Shakib S.

Aust Health Rev. 2014 Feb;38(1):51-7. doi: 10.1071/AH12027.

PMID:
24351707
14.

Is immediate imaging important in managing low back pain?

Andersen JC.

J Athl Train. 2011 Jan-Feb;46(1):99-102. doi: 10.4085/1062-6050-46.1.99.

15.

A comparison of active surveillance programs including a spontaneous reporting model for phamacovigilance of adverse drug events in a hospital.

Yun IS, Koo MJ, Park EH, Kim SE, Lee JH, Park JW, Hong CS.

Korean J Intern Med. 2012 Dec;27(4):443-50. doi: 10.3904/kjim.2012.27.4.443. Epub 2012 Nov 27.

16.

Computerized surveillance of adverse drug events in hospital patients.

Classen DC, Pestotnik SL, Evans RS, Burke JP.

JAMA. 1991 Nov 27;266(20):2847-51. Erratum in: JAMA 1992 Apr 8;267(14):1922.

PMID:
1942452
17.

Influence of attitudes on pharmacists' intention to report serious adverse drug events to the Food and Drug Administration.

Gavaza P, Brown CM, Lawson KA, Rascati KL, Wilson JP, Steinhardt M.

Br J Clin Pharmacol. 2011 Jul;72(1):143-52. doi: 10.1111/j.1365-2125.2011.03944.x.

18.

Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care.

Weeks G, George J, Maclure K, Stewart D.

Cochrane Database Syst Rev. 2016 Nov 22;11:CD011227. Review.

PMID:
27873322
19.

Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group.

Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R, et al.

JAMA. 1995 Jul 5;274(1):29-34.

PMID:
7791255
20.

Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.

Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, Hazell L, Krska J, Lee AJ, McLernon DJ, Murphy E, Shakir S, Watson MC.

Health Technol Assess. 2011 May;15(20):1-234, iii-iv. doi: 10.3310/hta15200. Review.

Supplemental Content

Support Center